直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
Paul W. Browning, Ph.D.
Partner
More
vCard
  • 901 New York Avenue, NW
  • Washington, DC 20001-4413
+1 202 408 4134
paul.browning@finnegan.com paul.browning@finnegan.com

Paul W. Browning, Ph.D.

Partner

  • +1 202 408 4134 +1 202 408 4134
  • paul.browning@finnegan.com paul.browning@finnegan.com
  • 901 New York Avenue, NW
  • Washington, DC 20001-4413
  • vCard

Paul Browning, Ph.D., is a first chair litigator focusing on patent litigation and appeals, primarily in the chemical and pharmaceutical areas, including Hatch-Waxman litigation. He has tried cases before judges in various U.S. district courts and has handled arbitrations and mediations. He also advises on patent portfolio strategy with an eye toward success in litigation.

Paul’s broad litigation experience includes taking and cross-examining witnesses at trial, briefing and arguing dispositive motions, drafting appellate briefs, and arguing cases on appeal. He has also managed day-to-day litigation activities in actions involving multiple parties. In addition to his litigation practice, Paul advises clients on a variety of patent matters, including strategic development of their patent portfolios and coordination of prosecution and U.S. and foreign litigation strategy and related proceedings before the Patent Trial and Appeal Board (PTAB).

Paul has been recognized as a litigation star by Benchmark Litigation and Managing Intellectual Property (MIP) named him as a notable practitioner in the District of Columbia. Paul frequently lectures on various topics in chemical patent law. He designed laser systems and conducted spectroscopy of small molecules while earning master’s and Ph.D. degrees at the University of Chicago.


Paul devotes a portion of his practice to pro bono matters and previously led the firm’s pro bono committee. He represents military personnel seeking enhanced compensation for injuries received while serving in the military, including injuries received in combat. He also represents veterans in cases before the U.S. Court of Appeals for Veterans Claims and the U.S. Court of Appeals for the Federal Circuit.

Et Cetera

  • Coauthor. “Patent Subject Matter Eligibility: A Global Guide,” Globe Law and Business, 2021.
  • Capital Pro Bono Honor Roll, 2018, 2023; High Honor Roll, 2017.
  • Law clerk to the Honorable Glenn L. Archer, Jr., of the U.S. Court of Appeals for the Federal Circuit, 2000-2001.

Experience

Biogen International GmbH v. Teva Pharmaceuticals USA, Inc.

Represented Biogen in a Hatch-Waxman litigation involving 28 companies seeking FDA approval to market generic versions of Tecfidera®.

1:17-cv-00829, D. Del., Judge Noreika
1:17-cv-00116, N.D.W. Va., Judge Keeley

Vifor (International) AG and American Regent, Inc. v. Mylan Labs. Ltd. et al.

Represented Vifor and American Regent in two Hatch-Waxman Act cases against Mylan and Sandoz regarding their attempts to obtain FDA approval for their respective ANDAs directed to generic copies of Injectafer®. After a six-day bench trial, the cases resulted in a favorable settlement for our clients with a generic entry date well past the expiration of the composition patents.

3:19-cv-13955, 3:19-cv-16305, D.N.J., Judges Wolfson, Arpert

Ferring B.V. v. Allergan, Inc.

Represented Ferring in inventorship litigation, relating to desmopressin pharmaceutical compositions,  acting as co-lead counsel at trial.

1:12-cv-02650, S.D.N.Y., Judges Cott, Sweet

Otsuka Pharmaceutical Co., Ltd. v. Apotex Corp.

Represented Otsuka in 24 related Hatch-Waxman litigations concerning Otsuka’s Ability® tablet products and acted as lead counsel on appeal.

1:14-cv-01078, -04671, -02982, -07405, -05878, -06398 -08074 -03306, -06890, -05876, -08077, -03168, -07252, -07105 -05537, -03996, -06158, -04508, -04307, -06397, -07106, -01979, -03445; 1:15-cv-0161, -07584, -01585, -07803, -08830, -05109, -07802, -08955, -01716, -01967, -06353, -08305; 1:16-cv-05288, -05400, -05949, -07705 -02475, -02476, -08284, -05743, -00086, -08085, -00555, -00557, -07346, -06067, -00405, -00424, -05688, -09603; 1:17-cv-02754, -00392, D.N.J., Judges Simandle, Williams

Prosecuting patents for startup Hutchison Medipharma

Finnegan prepared and prosecuted patents for startup Hutchison Medipharma in the United States for the treatment of metastatic colorectal cancer. Those patents cover a small molecule, fruquintinib, which received approval in China.

Finnegan tees up valuable patents for Principia Biopharma, leading to major acquisition deal

Completed successful patent prosecution for Principia. By entrusting Finnegan to obtain strong patents for their Phase 1 candidate, Principia was able to secure an exclusive, worldwide license agreement with Sanofi to develop and commercialize PRN2246, with the potential for $765 million in milestone payments. Finnegan also successfully prosecuted patents directed to compound PRN1008, a BTK inhibitor that Principia is investigating for autoimmune and inflammatory diseases. Principia’s impressive pipeline of drug candidates, covered by a patent portfolio prosecuted by Finnegan, led to an IPO in which Principia raised over $100 million.

More

Insights

Conference

Life Sciences Patent Network North America Spring Life Sciences Patent Network North America Spring

April 29-30, 2026

Boston

Webinar

Inherency Doctrine in Patent Prosecution and Litigation 2025 Inherency Doctrine in Patent Prosecution and Litigation 2025

December 18, 2025

Webinar

Conference

The Carolina Patent, Trademark & Copyright Law Association Fall Meeting The Carolina Patent, Trademark & Copyright Law Association Fall Meeting

September 26-27, 2025

Kiawah Island

Articles

5 Tribunals' Rules To Help Patent Litigators Avoid AI Disasters

5 Tribunals' Rules To Help Patent Litigators Avoid AI Disasters 5 Tribunals' Rules To Help Patent Litigators Avoid AI Disasters

May 19, 2025

Law360

Prosecution First Blog

The USPTO’s “Experimental Use Exception Request for Comments” The USPTO’s “Experimental Use Exception Request for Comments”

July 12, 2024

Conference

Carolina Patent, Trademark & Copyright Law Association Fall CLE Carolina Patent, Trademark & Copyright Law Association Fall CLE

September 29-30, 2023

Kiawah Island

More

News

Award/Ranking

Finnegan Named a Tier 1 Firm in the 2026 Benchmark Litigation Rankings Finnegan Named a Tier 1 Firm in the 2026 Benchmark Litigation Rankings

October 28, 2025

Benchmark Litigation

Announcement

Finnegan Announces 2024 Mentors of the Year Finnegan Announces 2024 Mentors of the Year

December 31, 2024

Award/Ranking

Benchmark Litigation Ranks Finnegan a Tier 1 Firm and Recognizes Eight Partners as Litigation Stars

Benchmark Litigation Ranks Finnegan a Tier 1 Firm and Recognizes Eight Partners as Litigation Stars

September 26, 2024

Benchmark Litigation

Award/Ranking

Finnegan Ranks at the Top of the Managing Intellectual Property IP Stars Rankings Finnegan Ranks at the Top of the Managing Intellectual Property IP Stars Rankings

June 28, 2024

Managing Intellectual Property

Award/Ranking

60 Finnegan Attorneys Named to 2023 Capital Pro Bono Honor Roll

60 Finnegan Attorneys Named to 2023 Capital Pro Bono Honor Roll

May 15, 2024

Award/Ranking

Finnegan Receives Tier 1 Benchmark Litigation Rankings; Nine Attorneys Named Litigation Stars Finnegan Receives Tier 1 Benchmark Litigation Rankings; Nine Attorneys Named Litigation Stars

October 5, 2023

Benchmark Litigation
More

Professional Activities

  • National Veterans Legal Services Program
    (member, Board of Directors, 2023-present)
Admissions and Education

Admissions

  • U.S. Patent and Trademark Office
  • District of Columbia
  • Massachusetts
  • U.S. District Court, D. Massachusetts
  • U.S. Court of Federal Claims
  • Supreme Court of the United States
  • U.S. Court of Appeals, Veterans Claims
  • U.S. Court of Appeals, Eleventh Circuit
  • U.S. Court of Appeals, Federal Circuit

Education

Harvard Law School
J.D., cum laude, 1999
University of Chicago
Ph.D., Chemistry, 1996
University of Chicago
M.S., Chemistry, 1993
Brown University
B.S., Chemistry, magna cum laude, 1991

Clerkships

  • U.S. Court of Appeals, Federal Circuit, Hon. Glenn Archer

Paul's Practices

Global IP Enforcement, Litigation, and Trials
Arbitration and Other ADR
Branded Hatch-Waxman (ANDA) Litigation and Trials
Federal Circuit and Supreme Court Appeals
Patent Litigation and Trials
Prosecution and Portfolio Management
IP Portfolio Management
Patent Drafting and Prosecution

Paul's Industries

Chemicals, Industrials, and Materials
Chemical
Life Sciences
Pharmaceutical

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP